BioNxt Solutions Inc

As of June 30, 2026, BioNxt Solutions Inc carries a market capitalization of 27.76M, placing it among publicly traded companies globally. Its enterprise value stands at 31.14M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, BioNxt Solutions Inc has 136.09M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, BioNxt Solutions Inc maintains a current ratio of 0.19, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -106.89, indicating conservative leverage, while an interest coverage ratio of -5.06 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -846.36, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 19.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, BioNxt Solutions Inc's stock has declined approximately 63.44% over the past 52 weeks. The 50-day moving average sits at 0.21, while the 200-day moving average is 0.27.

Over the twelve months ended June 30, 2026, BioNxt Solutions Inc generated - - in revenue and converted that into -5.64M in net income, yielding earnings per share of -0.05. EBITDA reached -4.85M, while operating income came in at -4.21M.

As of June 30, 2026, BioNxt Solutions Inc holds 741,551.87 in cash and equivalents against 4.12M in total debt, resulting in a net debt position of 3.38M. Total book value stands at -3.86M, with working capital of -3.32M providing operational flexibility.

BioNxt Solutions Inc produced -2.81M in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -11.12: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -12.57, meaning BioNxt Solutions Inc raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, BioNxt Solutions Inc has an Altman Z-Score of -84.39, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.